Regorafenib
CAS 755037-03-7
Overview
Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition
Anant Labs manufacture and furnish high quality Regorafenib impurities for global markets. Our Regorafenib EP Impurities are used by API manufacturers and fully integrated pharmaceutical companies worldwide.
